Background: This study was performed to evaluate the pharmacokinetics, bioequivalence, and feasibility of a combined oral formulation of 5-flurouracil (5-FU) and eniluracil (Glaxo Wellcome Inc., Research Triangle Park, North Carolina), an inactivator of dihydropyrimidine dehydrogenase (DPD). The rationale for developing a combined eniluracil/5-FU formulation oral dosing form is to simplify treatment with these agents, which has been performed using separate dosing forms, and decrease the probability of severe toxicity and/or suboptimal therapeutic results caused by inadvertently high or conversely insufficient 5-FU dosing.
Introduction
5-FU has been the mainstay of therapy for many common malignancies, particularly colorectal cancer, despite modest response rates on conventional intermittent intraimprove the efficacy of 5-FU have focused on maximizing the conversion of 5-FU to its active metabolites, thereby enhancing the inhibition of thymidylate synthase and incorporation of active anabolites into both RNA and DNA. [1, 2] These strategies have utilized venous (i.v.) bolus dosing schedules. Most strategies to diverse approaches, including biochemical modulation, regional drug delivery, and protracted i.v. administration [1] . Protracted drug administration, especially in solid malignancies, appears rational from a pharmacologic standpoint since 5-FU-induced cytotoxicity is S-phasedependent, and systemic drug clearance, primarily by metabolic deactivation, is very rapid [3] . The results of a recent randomized clinical trial have also demonstrated that 5-FU administered by protracted i.v. infusion is at least as efficacious as and less toxic than shorter infusions of 5-FU administered with either leucovorin or L-aspartate [4] . A meta-analysis, involving 1219 patients with advanced colorectal cancer, also demonstrated that the response rate, survival, and safety of 5-FU are superior when the agent is administered as a protracted continuous i.v. infusion compared to i.v. bolus administration [5] . In spite of these potential advantages, protracted continuous i.v. administration of 5-FU is associated with increased cost, patient inconvenience, and complications due to the requirements for indwelling central venous catheters and ambulatory infusion pumps.
An alternate approach to achieving protracted 5-FU exposure is oral drug administration, but this approach has not been feasible until recently because the oral bioavailability of 5-FU is highly erratic, ranging from 0% to 80% [3] . There is also extensive intrasubject and intersubject variability in tissue concentrations of dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme involved in the catabolism of 5-FU [3, 6, 7] . This variable metabolism principally accounts for 5-FU's highly unpredictable and variable oral bioavailabilty, systemic clearance, and toxicity [6, 7] . Additionally, high concentrations of DPD in the liver result in extensive first-pass metabolism, variable and schedule-dependent clearance, and account for the rapid elimination (halflife (t 1/2 ) = 8-20 minutes) of greater than 70% of an administered dose of 5-FU [3] . Circadian fluctuations and genetic polymorphism in DPD activity, with severe deficiency of the enzyme in 2%-4% of the population, undoubtedly contribute to the large interindividual variability in 5-FU's systemic clearance and bioavailability [8, 9] . Wide variability in intratumoral DPD has also been documented and appears to be a negative determinant of 5-FU tumor responsiveness in patients with head and neck cancer [10] . In addition to the principal role of DPD in the rapid systemic clearance and erratic oral bioavailability of 5-FU, the end products of 5-FU metabolism, catalyzed by DPD, are inherently toxic [11, 12] . For example, a-fluoro-p-alanine (FBAL), the principal 5-FU metabolite, appears to be responsible for the neurotoxicity of 5-FU in both preclinical models and cancer patients [11, 12] . DPD also catalyzes the NADPH-dependent reduction of 5-FU to 5-fluoro-5,6-dihydrouracil (5-FUH 2 ), which has been demonstrated to reduce the anti-tumor activity of 5-FU and increase gastrointestinal toxicity in a rat model [13] .
The pharmacologic inactivation of DPD is an attractive strategy to improve the therapeutic index and feasibility of 5-FU by: (1) decreasing the formation of toxic metabolites; (2) enhancing antitumor activity by suppressing intratumoral 5-FU catabolism; (3) increasing the predictability of plasma disposition by decreasing interpatient variability in systemic clearance; (4) increasing the feasibility of oral administration since DPD is responsible for the catabolism and erratic absorption of oral 5-FU; and (5) providing the benefits of continuous i.v. administration of 5-FU without the requirements for central venous access and infusion pumps. Eniluracil (Glaxo Wellcome Inc., Research Triangle Park, North Carolina), a uracil analog with an ethynyl substituent at the 5' position, is a mechanism-based effective inactivator of DPD in vitro and in vivo [14] [15] [16] [17] [18] . In rats, a single oral dose of eniluracil inactivates greater than 99% of hepatic DPD, substantial decreases 5-FU clearance, and is 100% bioavailable [18] . In early clinical trials in patients with advanced solid malignancies, eniluracil significantly altered the disposition of 5-FU, resulting in mean terminal ti / 2 values of approximately 4.5 hours and complete oral bioavailability [17, [19] [20] [21] . Treatment of patients with eniluracil and oral 5-FU also enabled simulation of the 5-FU pharmacokinetic profiles achieved with common parenteral dose-schedules [19] [20] [21] . For example, 1 mg/m 2 of oral 5-FU administered twice daily with eniluracil 20 mg twice daily for 28 days is associated with 5-FU pharmacokinetic parameters that are nearly equivalent to those previously reported in the literature with protracted i.v. administration of 5-FU on clinically relevant dose schedules [21] . An evaluation of surrogate markers for DPD inactivation, including the clearance of uracil, 5-FU clearance, and the urinary excretion of 5-FU, and 5-FU catabolites, indicated that eniluracil doses exceeding 20 mg/day maximally inactivates DPD [16, 17, [19] [20] [21] .
By substantially decreasing 5-FU clearance and increasing oral bioavailabilty, the maximum tolerated doses of oral and i.v. 5-FU are much lower when 5-FU and eniluracil are administered together compared to 5-FU alone [17, [19] [20] [21] . Therefore, the administration of 5-FU and eniluracil together may lead to severe toxicity if patients inadvertently ingest higher than appropriate 5-FU doses. The development of an oral combined eniluracil/5-FU formulation would be expected to decrease such dosing errors and increase the overall feasibility of therapy with eniluracil and 5-FU. The principal objectives of this study were to assess the pharmacokinetics, bioequivalence, and feasibility of an oral tablet containing both 5-FU and eniluracil together by comparing two strengths of a combined eniluracil/5-FU formulation to the separate eniluracil and oral 5-FU formulations used in clinical trials to date.
Patients and methods

General design
The study (FUMA1006) was a randomized, open label three-way crossover bioequivalence study of three oral dosing forms of eniluracil/5-FU tablets in adults with solid malignancies conducted at the Institute for Drug Development of the Cancer Therapy and Research Center, San Antonio, Texas, Duke University Medical Center, Durham, North Carolina, and the University of Wisconsin, Madison, Wisconsin. The study compared two strengths of combined eniluracil/5-FU tablets to individual, separate eniluracil and 5-FU tablets that have been used in clinical studies to date. Eligible patients were randomly assigned to one of six treatment sequences consisting of three different treatment schemes (treatments A, B, and C) as shown in Table 1 . As part of the crossover design of the study, each patient served as his or her own control. All three treatment schemes consisted of two days of treatment followed by a five-day washout phase. To ensure maximum inactivation of DPD on day 2, eniluracil 20 mg was administered as a single agent twice on day 1 and as a single evening dose on day 2 of the three treatment schemes [16, 17, [19] [20] [21] . On the morning of day 2, all patients received a total eniluracil dose of 20 mg with a total 5-FU dose of 2.0 mg as either separate tablets of each agent (treatment A, two 10 mg eniluracil tablets mg plus two 1 mg 5-FU tablets) or one of two strengths of a combined eniluracil/5-FU (mg/mg) tablet (treatment B, two combined 10/1 tablets; or treatment C, eight combined 2.5/0.25 tablets). Blood sampling and 24-hour urine collections were obtained for each patient up to 24 hours after treatment to ascertain information on the pharmacokinetics of 5-FU and eniluracil, from which to assess bioequivalence. Following the bioequivalence study, patients were able to receive chronic treatment with eniluracil and 5-FU in a follow-up open-label study that utilized a 28-day treatment schedule of both agents [21] . They were able to continue treatment in the subsequent study in the absence of disease progression or intolerable toxicity.
Eligibility
Patients with histologically documented assessable or measurable solid malignancies refractory to conventional therapy or for whom no effective therapy existed were candidates for this study. Eligibility criteria included: age of 18 or older; a Karnofsky Performance Status of 70% or greater (ambulatory and capable of self-care); a life expectancy of at least 12 weeks; ability to swallow and retain oral medications; no evidence of malabsorption nor gastrointestinal dysfunction; no prior resection of the stomach or small bowel; adequate hematopoietic (absolute neutrophil count (ANC) 3= 2000/ul, platelets 5= 100,000/ul, hemoglobin 5= 9.0 g/dl), hepatic (total bilirubin < 1.25 times the upper limit of institutional normal and aspartate amino transferase (AST) and alanine amino transferase (ALT) s£ 3.0 times the upper limit of institutional normal ^ 5.0 times the institutional normal upper limit if the transaminase elevation was due to the malignant disease) and renal (creatinine clearance > 50 ml/minute calculated according to the method of Cockcroft and Gault) functions [22] ; no co-existing medical condition of sufficient severity to limit full compliance with the study; no clinically-significant effusions or peripheral edema; no treatment with wide-field radiation therapy, chemotherapy, hormonal therapy, or biological therapy within the previous 28 days (42 days for nitrosoureas or mitomycin-C); no concurrent treatment nor treatment within 14 days with dipyridamole, folinic acid, allopurinol, trimethoprim, misonidazole, metoclopramide, flucytosine or cimetidine; and no major surgery within 14 days. All patients gave informed written consent according to federal and institutional guidelines. Patients who met the eligibility criteria and gave written informed consent were assigned consecutive study numbers in the order of registration, and one of six sequence iterations of treatments A, B and C were randomly assigned to treatment numbers.
Drug administration and dosage
Eniluracil was provided as round, off-white, 7.4 mm, 10 mg tablets and 5-FU was supplied as reddish-brown, round, 7 mm, 1 mg tablets by Glaxo Wellcome Inc. The combination dosing forms were capletshaped, white and pink film-coated tablets comprised of eniluracil and 5-FU (eniluracil/5-FU [mg/mg]) in 10/1 and 2.5/0.25 strengths, respectively. Eniluracil 20 mg was administered as single agent twice on day 1 and as a single evening dose on day 2 of all three periods. On the morning of day 2, 20 mg of eniluracil was given along with 2 mg of 5-FU either as separate tablets (treatment A) or combined tablets (treatment B and C). Each dose of eniluracil was administered 12 hours apart with six to eight ounces of water. Patients fasted for one hour before and after treatment with eniluracil. When patients were treated with separate tablets (treatment A), each dose of 5-FU dose was administered with six to eight ounces of water immediately after treatment with eniluracil. Patients fasted for one hour after treatment with 5-FU. AH treatment periods were separated by a five-to seven-day washout phase.
There were no dose modifications during the bioequivalence study. A platelet count > 75,000/ul and a ANC > 1500/ul, as well as resolution of clinically-significant drug-induced nonhematologic effects including diarrhea, mucositis and hand-foot syndrome, were required for retreatment after each washout period. Patients who required a treatment delay exceeding three weeks due to unresolved toxicity were taken off-study. If treatment with 5-FU was either discontinued or delayed for any reason, treatment with eniluracil was also discontinued or delayed. Drug administration during treatments A, B, and C was always performed in the presence of research study personnel. 
Pretreatment and follow-up studies
An interval history that included recording of performance status and concurrent medications, physical examination, and routine laboratory evaluation were performed pretreatment and weekly before treatments A, B, and C. Routine laboratory evaluations included complete blood counts, differential WBC counts, electrolytes, blood urea nitrogen creatinine, glucose, total protein, albumin, calcium, phosphate, uric acid, alkaline phosphatase, total and direct bilirubin, AST, ALT, prothrombin time, and urinalysis. Pretreatment studies also included an electrocardiogram, pregnancy test for women of childbearing potential, and relevant radiological studies for evaluation of all measurable and evaluable sites of malignancy, as well as an assessment of relevant tumor markers. Interval histories, specifically directed at assessing drug-related toxicity, performance status, physical examination, and recording of weight, were performed 72 hours after the first dose of study drug during treatments A, B, and C, as well as 7 to 14 days after the last dose of study drugs. Because corneal effects were noted in dogs treated with high doses of eniluracil, opthalmologic examinations, including a slit-lamp evaluation, were performed pretreatment and after the bioequivalence stage of the study. Toxicity was graded using Southwest Oncology Group criteria.
Pharmacokinetic studies
To study the pharmacokinetics of eniluracil and 5-FU, and the bioequivalence of these agents following treatment with all dosing forms, and evaluate the effects of treatment on plasma uracil, 4-ml blood samples were collected in heparin-containing vacutainer glass during treatments A, B, and C in all patients. Blood sampling was performed before the first dose of eniluracil on day 1, and at 6, Pooled urine specimens were collected continuously for 24 hours beginning immediately after the morning dose of study drug on day 2 in 0-6 hour, 6-12 hour, and 12-24 hour timed collections. The collections were refrigerated throughout. After the urine collections were shaken, 50-ml aliquots were drawn off and frozen at -20 °C in a labeled sample tube until analysis for 5-FU, FBAL, eniluracil and uracil.
A validated analytical method liquid-liquid extraction and derivatization with gas chromatography/mass spectroscopy was used to determine concentrations of 5-FU, eniluracil, uracil, and FBAL in plasma and urine [20, 21] . Whenever possible, samples from the same subject were run in the same analytic batch to minimize the effects of interassay variation. In plasma, the concentration ranges for the calibration curves were 1-1000 ng/ml for both eniluracil and 5-FU, and 100-6000 ng/ml for uracil. The interassay precision (% coefficient of variation (%CV)) and accuracy (% of nominal) were: 6.4%-14.0% and 90.5%-101.8%, respectively, for 5-FU; 4.7%-8.0% and 97.0%-106.6%, respectively, for eniluracil; 4.3%-7.3% and 93.0%-105.7%, respectively, for uracil. In urine, the concentration ranges for the calibration curve were 0.1-100 ug/ml, 0.01-1.0 ^g/ml, 0.01-10 ug/ml, and 10-500ug/ml for 5-FU, FBAL, eniluracil, and uracil, respectively.
Pharmacokinetic analysis
The pharmacokinetics of eniluracil, 5-FU, and uracil in plasma were analyzed using standard noncompartmental methods with WinNonlin Pro, Version 1.5 (Scientific Consulting, Inc, Apex, North Carolina). The area under the concentration-time curve up to the last sampling time (AUCo-iast) was calculated as AUCo-iast + Qast'^i where Q asl was the last measured concentration and X z , was determined from the terminal slope of a semi-logarithmic plot of concentration-time data. The half-life (t; 2 ) was calculated as In 2/?^; the apparent clearance (CL/F) was calculated as Dose/AUC 0 _co, and the apparent volume of distribution (V 2 /F) was calculated as the Dose/t^AUC^,); C max and its associated time (t max ) were determined by inspection of the concentration-time curves.
Median and mean concentration-time profiles were calculated for eniluracil (uncorrected and corrected) for carryover from day 1 dosing, 5-FU, and uracil using protocol-sampling times. Concentrations below quantitation limit (BQL) were treated as zero in the calculation of the median concentration-time profile. Prior to C max , all BQLs were treated as zero in the calculation of AUC 0 _i ast and AUCo-coi after C m ax these time points were not considered as AUCo-co was extrapolated from the last quantifiable concentration. Actual blood sampling times were used for all pharmacokinetic calculations. The data points used to estimate X z was selected after graphical inspection of the data and a minimum of three data points was used.
Eniluracil plasma pharmacokinetic data were collected after treatment on day 2. When there was evidence of residual eniluracil from treatment on day 1, the concentration-time profiles for eniluracil from 0-12 hour after treatment were corrected for the amount remaining from the day I dose as follows: (1) X z values were calculated for each patient-treatment combination using the terminal portion of the curve after the eniluracil dose on day 2; (2) The corrected eniluracil plasma concentration derived from only 0 to 12 hours after treatment on day 2 was calculated as C corr(t) = C O b S (t) -C O bs(0)e~X zl , where C corr(t) is the corrected plasma concentration at time t after the dose on day 2, C obS (i) is the observed plasma concentration at time t after the dose on day 2, Cobs(0) is the observed plasma concentration at time 0 on day 2, X z is the elimination rate constant determined from the day 2 data, and t is the time since the dose on day 2. The resulting C corr data were subjected to standard noncompartmental analysis as previously outlined. C max and AUCo_i a si were also calculated from the uncorrected eniluracil plasma concentration-time data for comparison. C max , t max and AUCo-i as t values were calculated for uracil from the 0-12 hour uracil plasma concentration-time data following the dose of eniluracil on day 2.
The total amount of unchanged 5-FU and FBAL excreted in the urine (Aeo-24) from 0 to 24 hours after treatment on day 2 were calculated and expressed as percentage of the dose. The total percentage of the dose of 5-FU that was recovered in the urine was calculated as the sum of the percentage of dose excreted as 5-FU and FBAL. The renal clearance of 5-FU was calculated as follows: CL r = Aeo-24/ AUCo-24-If no plasma concentration was available at 24 hour, AUCo-24 was calculated using the extrapolated or interpolated concentration.
Statistical analysis
The primary statistical analyses of C max , AUCi ast and AUCj,, for eniluracil (corrected and uncorrected) and 5-FU were performed after log-transformation of the data. C max , AUC 0 _i asI and AUC 0 -co values for eniluracil and 5-FU were compared between treatment groups (i.e. each strength of the combination eniluracil/5-FU tablet and the individual eniluracil and 5-FU tablets) using 90% confidence intervals derived from two one-sided t-tests. This was accomplished by the analysis of variance (ANOVA) taking into account sources of variation due to patient, sequence, subject within sequence, period and treatment. Prior to this analysis, a preliminary analysis, including a carryover variable (defined as treatment received in the previous period) was performed. Summary statistics including 95% confidence intervals were calculated for each treatment group. The geometric least squares (LS) means, mean ratios, and associated 90% confidence intervals were computed to compare the treatment groups. For the analysis performed without log transformations, the least squares mean treatment group differences were computed to compare the treatment groups. Residuals from all parametric analyses were examined for outliers and evidence of normality. The criteria for bioequivalence were met if the ANOVA showed that the 90% confidence interval of the mean ratios (treatment B/A or C/A) of pertinent pharmacokinetic variables were within the range of 80% to 125%.
Nonparametric methods were used to compute medians on t max for each treatment group, and the median differences and associated 90% confidence intervals for t max between treatment groups were computed [23] , Other pharmacokinetic parameters, including X z , t 1/2 , CL/F V z /F, and CL r were compared across treatment groups using descriptive statistics.
Results
General
Forty-one patients, whose pertinent characteristics are listed in Table 2 , were entered onto the study. Thirtynine patients completed treatments A, B, and C, and were fully evaluable for bioequivalence assessments. Treatment was discontinued in two subjects during the bioequivalence phase of the study, one patient whose disease progressed and a second patient whose renal function did not meet the criterion for retreatment.
Eniluracil pharmacokinetics
Eniluracil plasma concentration-time profiles and pharmacokinetic parameters after treatments A, B, and C were similar, as shown in Figure 1 and Table 3 . Two individuals had atypically low plasma eniluracil concentrations following treatment A (separate eniluracil and 5-FU tablets) compared to treatments B and C, and an inspection of their plasma concentration-time data sets revealed a steady decline in plasma concentrations without a characteristic absorption phase, which indicated that these patients may not have taken their eniluracil tablets on day 2. Therefore, all pharmacokinetic parameter derivations and statistical analyses were performed with and without these patients' data. Eniluracil was rapidly absorbed, with mean C max values occurring 2.00, 1.52, and 1.52 hours after drug administration following treatment A, B, and C, respectively. Plasma eniluracil concentrations declined in a monophasic manner, with elimination ti/ 2 values averaging 4.2 ± 3.4 hours, 3.5 ± 0.7 hours, and 3.7 ± 1.0 hours hours in treatment periods A, B, and C, respectively. Interindividual variability was modest, with coefficients of variation ranging from 23% to 33% for AUC and CL/F values.
5-FU pharmacokinetics
The 5-FU pharmacokinetic parameters following treatments A, B, and C are listed in Table 4 , and mean 5-FU plasma concentration-time curves are displayed in Figure 2 . The absorption of 5-FU was rapid following treatments A, B, and C, with C max values averaging 1.2, 1.5, and 1.25 hours, respectively. Plasma 5-FU concentration-time profiles were similar among the three treatments and there were no significant differences in relevant pharmacokinetic parameters. Interestingly, the low plasma concentrations of eniluracil following treatment A in the two outliers did not affect the pharmacokinetic behavior of oral 5-FU in these individuals, most likely due to the protracted DPD-inactivating effects of eniluracil administered on day 1. There were no significant differences in the urinary excretion of a Values represent the means ± standard deviation; the t max value represents median (range). All patients were treated with eniluracil 20 mg twice on day 1 and as a single evening dose on day 2. On the morning of day 2, all patients received a total eniluracil dose of 20 mg with a total 5-FU dose of 2.0 mg as two tablets containing eniluracil 10 mg alone plus two tablets containing 5-FU 1 mg alone (treatment A) or two tablets of a combined eniluracil 10 mg/ 5-FU 1 mg formulation (treatment B) or eight tablets of a combined eniluracil 2.5 mg/5-FU 0.25 mg formulation (treatment C).
urine as FBAL averaged 1% (range, 0-7.6%), with mean Ae o _24 values of 1.2%, 0.8%, and 0.7% during treatment periods A, B, and C, respectively.
Plasma uracil profiles
Pertinent pharmacokinetic parameter values for uracil are depicted in Table 5 . Plasma uracil concentrationtime profiles and pertinent pharmacokinetic parameters (C m a x , t max , and AUC 0 _iast) were similar amongst the three treatment types, as shown in Figure 3 . Plasma uracil concentrations increased rapidly following eniluracil treatment on day 1 and generally plateaued at approximately eight hours after treatment on day 2. The urinary excretion of uracil following treatment with eniluracil/5-FU was similar amongst the three treatment types, with Ae )2 values averaging 113, 123, and 119 mg following treatment A, B and C, respectively.
Bioequivalence
Analyses of eniluracil and 5-FU bioequivalence between treatments A and B and treatments A and C were performed. The analyses focused on C m a x , t m a x , AUCo_ia S t, AUCo-oo values and both included and excluded the two outliers who likely did not receive eniluracil on day 2 of treatment A. From the analysis for uncorrected eniluracil with all patients included, only AUC 0 _iast rnet bioequivalence criteria for the groups. However, when the formerly referred subjects were excluded from the analysis, both C m a x and AUC 0 _i a st met the criteria. For corrected eniluracil with the two outliers excluded, all pharmacokinetic parameters met bioequivalence criteria for the between-group comparisons. The ratios (90% confidence intervals) of eniluracil AUCn-iast for B/A and C/A were 1.07 (1.02, 1.12) and 1.07 (1.02, 1.12), respectively, and comparable values for AUCo_ ro were 1.02 (0.99, 1.06) and 1.03 (0.99, 1.06), respectively. The results of the analyses of bioequivalence for C m a x , t max , AUCo_i ast , AUCo_oo for 5-FU between groups B and A and groups C and A met the bioequivalence criteria irrespective of the type of analysis. The ratios (90% confidence intervals) of 5-FU AUC 0 _iast for B/A and C/A were 1.00 (0.97, 1.03) and 1.02 (0.99, 1.05), respectively, and comparable values for AUCo-o, were 1.00 (0.97, 1.04) and 1.02 (0.99, 1.05), respectively.
Adverse events
The most common adverse events ( > 5 % of patients), which may or may not have been due to study drug, are displayed in Table 6 . Thirty-five patients (85%) experienced at least one adverse event during the bioequivalence study (treatments A, B, and C). The organ systems 
a All patients were treated with eniluracil 20 mg twice on day 1 and as a single evening dose on day 2. On the morning of day 2, all patients received a total eniluracil dose of 20 mg of eniluracil with a total 5-FU dose of 2.0 mg as two tablets containing eniluracil 10 mg alone plus two tablets containing 5-FU 1 mg alone (treatment A) or two tablets of a combined eniluracil 10 mg/5-FU 1 mg formulation (treatment B) or eight tablets of a combined eniluracil 2.5 mg/5-FU 0.25 mg formulation (treatment C).
with the most common adverse events were gastrointestinal (54% of patients), non-site specific (41%), skin (20%), and neurologic (15%). Fifty-nine percent and 20% of patients experienced adverse events with a maximal severity of grade 1 and grade 2, respectively. Three patients experienced severe (grade 3 or 4) adverse events. These included grade 3 dyspnea, which was probably due to the underlying disease (one subject), and grade 3 nausea and vomiting along with an exacerbation of chronic obstructive pulmonary disease (one subject). The third subject with severe toxicity experienced grade 4 mucositis, grade 4 neutropenia, and grade 3 thrombocytopenia 23 days after permanently discontinuing eniluracil. This patient had inadvertently been treated with a five-day course of 5-FU and leucovorin at another institution two weeks after participation in the bioavailability phase of the study. Eleven patients (27%) experienced adverse events that were considered to be possibly due to the study drugs. Only 2 types of these drug-related adverse events were reported for more than one patient: nausea (n = 6 (15%); treatment A, n -2; treatment B, n = 3; treatment C,n= 1) and malaise and fatigue (n -3 (7%); treatment B, n -3). Detailed opthalmologic examinations performed on all patients before and after the three treatment periods were unremarkable. Only one patient reported ocular complaints consisting of a headache and seeing 'dancing mirror-like tiles' during treatment B.
Discussion
The inactivation of DPD by eniluracil is potentially a highly effective means of increasing the therapeutic index of 5-FU, particularly when the agent is administered by the oral route, which, historically, has been associated with unpredictable pharmacokinetics and erratic toxicity [17, [19] [20] [21] . The results of early clinical studies of eniluracil have indicated that DPD is principally responsible for the disposition of 5-FU, its erratic oral bioavailablity, and large intersubject variation in pharmacokinetics and toxicity [3, [6] [7] [8] [9] . In fact, an oral dose of 5-FU (1.0 mg/m 2 ) twice daily administered with eniluracil 20 mg twice daily results in pharmacokinetic parameters that are similar to those achieved with 5-FU as a protracted i.v. infusion at a dose of 300 mg/m 2 /day [21] . The inactivation of DPD is attractive for 5-FU modulation because it may: (1) ensure predictable oral administration of 5-FU since DPD is principally responsible for the catabolism and erratic bioavailability of oral 5-FU; (2) result in more predictable pharmacologic and toxicologic profiles by decreasing intersubject variability in 5-FU clearance; (3) improve the toxicity profile of 5-FU by decreasing the formation of toxic metabolites; (4) enhance antitumor activity by suppressing 5-FU catabolism in tumors; and (5) provide the benefits of continuous 5-FU administration without requiring central venous access and cumbersome infusion pumps.
From a pharmaceutical standpoint, the availability of 5-FU and eniluracil as separate oral dosing forms increases the likelihood of administering inadvertently high or low doses of 5-FU. The most serious concern is that the inadvertent administration of even a slightly higher than appropriately dose of 5-FU in an eniluracilinduced DPD-deficient state may result in severe toxicity. Additionally, the availability of separate oral dosing forms increases the likelihood that patients will be treated with inappropriately low doses of eniluracil, which can result in low 5-FU absorption and therapeutic efficacy. For these reasons, a combined oral eniluracil/5-FU formulation (eniluracil/5-FU (mg/mg)) in two different strengths (10/1 and 2.5/0.25) is being developed. The principal objective of the present study was to characterize the pharmacokinetics of oral 5-FU and eniluracil, while evaluating the bioequivalence of combined and separate eniluracil/5-FU formulations.
This study demonstrated that both strengths of the combined 5-FU/eniluracil tablet formulation are well absorbed and result in plasma concentration-time profiles similar to those achieved with separate eniluracil and 5-FU tablets. Although intersubject variability in the harmacokinetics of both 5-FU and eniluracil was noted, the intersubject coefficients of variation for relevant pharmacokinetic parameters (i.e. AUC and clearance) ranged from 22% to 33%. This range is substantially less than the five-fold intersubject variability in comparable parameters in patients treated with 5-FU alone [6, 10, 23, 24] . In addition, population studies have suggested that the substantial interpatient variability in DPD activity, which, in turn, accounts for the wide intersubject variability in 5-FU clearance, susceptibility to toxicity, and therapeutic efficacy in the clinic. The results of the present study corroborate those of previous studies of oral 5-FU and eniluracil, which have shown that eniluracil substantially reduces intersubject variability in 5-FU pharmacokinetics. In this study, 5-FU pharmacokinetic parameters following treatment with either separate or combined eniluracil/5-FU dosing forms were nearly identical. DPD inactivation by eniluracil substantially reduced 5-FU clearance and resulted in mean terminal t 1/2 values of 5.5 ± 1.2 hours, 5.6 ± 1.2 hours, and 5.6 ± 1.2 hours following treatment with the separate tablets (treatment A), the combined high-dose formulation (treatment B), and the combined low-dose formulation (treatment C), respectively. In contrast, 5-FU terminal t\ /2 values in the range of eight to 20 minutes have been reported following treatment with 5-FU administered intravenously without modulation [3] . Similar to previous studies of 5-FU and eniluracil, the present study demonstrated that most of the administered dose of 5-FU is eliminated as unchanged drug (mean, 55% (range, 14.7%-112.3%)) over 24 hours, and the excretory profiles of 5-FU following each of the three types of treatments were nearly identical [19] [20] [21] . The results also indicate that the principal route of 5-FU elimination is shifted from DPD-related metabolism to renal excretion. This is consistent with the results of previous studies of eniluracil/5-FU, in which the clearance of 5-FU is reduced approximately 20-fold to values comparable to the glomerular filtration rate («100ml/min).
Several indices reflecting DPD inactivation were also evaluated to compare DPD inactivation due to the three types of treatment. Since uracil is an endogenous substrate for DPD and more than 95% inactivation of DPD by eniluracil is required to maintain maximally elevated plasma uracil concentrations in vivo [25] , plasma uracil was measured to gauge the extent of DPD inhibition following treatment with eniluracil/5-FU. In individuals with normal DPD activity, plasma uracil concentrations are generally maintained at levels below 100 ng/ml [26] ; however, uracil C max values averaged 3,146 ± 879 ng/ml, 3,145 ± 880 ng/ml, and 3,086 ± 702 ng/ml following the administration of eniluracil/5-FU in treatment arms A, B, and C, respectively, and steady-state uracil concentrations ranged from 3,000 to 4,000 ng/ml in all treatment arms. These results are nearly identical to those reported previously with eniluracil/5-FU, with the behavior of all indices of DPD inhibition, suggesting that DPD is maximally inactivated following treatment with 10 to 20 mg of eniluracil administered twice daily [20] . In fact, complete inactivation of intratumoral DPD has been documented in colorectal patients treated with eniluracil in this dosing range [16] . Furthermore, unmetabolized 5-FU was principally and similarly excreted in the urine following treatment with all three eniluracil/5-FU treatment schemes, and the urinary excretion of the neurotoxic metabolite FBAL was negligible -less than 1%, irrespective of the treatment scheme. The urinary recovery of FBAL, the final product of 5-FU catabolism, was another surrogate marker used to monitor and compare the extent of DPD inactivation achieved in the eniluracil/5-FU treatment arms. When 5-FU is given alone, more than 50% of the 5-FU dose is recovered from the urine as FBAL [3] . Higher doses of eniluracil (up to 50 mg/day) have not been demonstrated to further reduce the recovery of 5-FU as FBAL in urine, which, along with the cumulative results of clinical studies to date, indicate that eniluracil doses of 10 to 20 mg twice daily maximally inactivate DPD [19, 21] . 5-FUH 2 , which is a catabolite formed by the NADPH-dependent reduction of 5-FU by DPD that appears to impair the anti-tumor activity and increase the toxicity of 5-FU in preclinical studies, was not measured in the present study [13] . The formation of this catabolite has also been demonstrated to be drastically reduced by eniluracil, and it is unlikely that its formation and excretion would differ amongst treatment arms A, B, and C in light of the nearly identical profiles demonstrated for 5-FU, uracil, and FBAL [19] [20] [21] .
An evaluation of bioequivalence demonstrated that the 90% confidence intervals of the mean ratios (treatments B/A and C/A) of C max , AUC 0 -i a st> and AUC 0 -oc were within the range of 80% to 125% for both eniluracil and 5-FU, fulfilling a standard and reasonable criteria for bioequivalence. For the principal therapeutic moiety, 5-FU, the criteria for bioequivalence were met regardless of whether the two outliers with low eniluracil concentrations during treatment A were included in the analyses. In fact, although inspection of eniluracil plasma concentrations of these subjects suggested that eniluracil was not ingested on day 2, their 5-FU plasma concentration-time curves resembled those of the other subjects. In addition to demonstrating the need to minimize such episodes, perhaps by using a combined eniluracil/ 5-FU dosing form, the similarity of 5-FU pharmacokinetics in these individuals to the other patients demonstrates that DPD is effectively inactivated following treatment with eniluracil 20 mg twice daily on day 1.
Although the toxicities of eniluracil/5-FU were generally mild to modest in all three treatment arms, the dose-schedule used in this bioequivalence study was selected to principally address pharmacokinetic and bioequivlence issues, and not to simulate 5-FU on a clinically-relevant dose schedule. Nevertheless, there were no unexpected toxicities during the short duration of the three types of eniluracil/5-FU regimens. However, because DPD is inactivated and requires regeneration following treatment with eniluracil, the inadvertent administration of 5-FU shortly after treatment with an appropriate eniluracil/5-FU regimen must be avoided. The severe toxicities, consisting of grade 4 neutropenia, grade 3 thrombocytopenia, and grade 4 mucositis, occurring 23 days after the last dose of study drug in a patient who had inadvertently been treated with a standard dose of 5-FU at another institution two weeks after participation in the bioavailability phase of the study, illustrates the need to establish rigorous safety measures in patients treated with eniluracil/5-FU.
The results of the present study indicate that 5-FU pharmacokinetic profiles are more desirable following treatment with eniluracil/5-FU than with conventional 5-FU dose-schedules without DPD modulation. From both pharmacologic and toxicologic standpoints, eniluracil provides an attractive means of administering oral 5-FU, by minimizing the deleterious effects of variable DPD activity. The results of this study also demonstrate that the bioequivalence of different strengths of combined eniluracil/5-FU tablets is nearly identical to the separate oral eniluracil and 5-FU formulations. The availability of a combined eniluracil/5-FU oral dosing form will not only simplify dosing, but it would likely decrease the probability of severe toxicity or suboptimal therapeutic results due to inadvertent or insufficient 5-FU dosing compared to separate eniluracil and 5-FU dosing forms, thereby increasing the feasibility of oral 5-FU therapy. Nevertheless, it is still be important to define the overall therapeutic impact of oral eniluracil/ 5-FU on the therapeutic index of 5-FU, which is undergoing evaluation.
